Navigation Links
ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
Date:4/8/2008

d be available by the middle of this year. Once we have reviewed the data from this study, we will decide on our future development plans with microplasmin for the treatment of acute stroke."

About Stroke

Stroke is a cardiovascular disease affecting the blood vessels of the brain. Stroke is caused by a blockage of the blood vessels of the brain, depriving the brain of oxygen, and can result in severe neurological damage and death. After heart diseases and cancer, stroke is the third most frequent cause of death and the leading cause of disability in the Western world. It is estimated that over two million people suffer a stroke annually. Mortality is high with 20% of patients dying, while the majority of the remainder are left permanently disabled.

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases such as acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in late 2008, and TB-403 (Anti-PlGF), which has begun Phase I clinical trials for the treatment of cancer. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-loo
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics Announces 2007 Full Year Results
2. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
3. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
4. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
5. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
6. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
7. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
8. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
9. Compressus Completes Interoperability Implementation for E-Rad Solutions Teleradiology Customers
10. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
11. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... 2015 Materials in Society Lecture ... June 30 2015   Elsevier , a ... services and publishing home of Materials Today , announced ... Materials in Society  Lecture Series . ... th International Conference on Materials for Advanced Technologies (ICMAT) ...
(Date:3/31/2015)... 2015  The Myeloma Crowd Research Initiative (MCRI) ... ten proposals that will now be evaluated for ... scientifically validated funding initiative uncovering solutions for high-risk ... the MCRI included preliminary vetting by the Scientific ... number of innovative projects focusing on high-risk myeloma, ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Diasome Pharmaceuticals, ... licensor, SDG, Inc., that a United States patent has ... insulin therapy. , Entitled “Lipid Construct for ... composition of matter claims related to the use of ... for enabling injected insulin to more effectively reach the ...
(Date:3/30/2015)... Struggles (Nasdaq: HSII ), the premier provider of ... shaping worldwide, today  announced that John Mitchell ... Life Sciences practice. As Global Practice Managing Partner ... of more than 80 partners, principals and associates in the ... serving clients in the biopharmaceutical, medical technology and ...
Breaking Biology Technology:Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 2Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 3Myeloma Crowd Research Initiative Selects 10 High-Risk Multiple Myeloma Proposals For Further Review 2Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2
... a life sciences company pioneering development of solid-state ... demonstrating the first direct electronic re-sequencing and mapping ... Advances in Genome Biology and Technology (AGBT) meeting, ... and the Omics and Personalized Medicine Conference at ...
... ago today, a task force comprised of Indianapolis business, ... strategy for Indiana,s life sciences sector that would catapult ... research institutions into a 21st-century hub for biotechnology and ... driven the state into the national spotlight as a ...
... 2012 Gen-Probe Incorporated (NASDAQ: GPRO ... 2011.  Total revenues in the quarter grew 16%, to a ... (EPS) increased 18%, to a new high of $0.72. ... in the fourth quarter while clinical diagnostics revenues continued their ...
Cached Biology Technology:Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and Technology (AGBT) Meeting and the EMBL Omics and Personalized Health Conference 2Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and Technology (AGBT) Meeting and the EMBL Omics and Personalized Health Conference 3BioCrossroads Commemorates Decade of Collaboration, Success for Indiana Life Sciences Sector 2BioCrossroads Commemorates Decade of Collaboration, Success for Indiana Life Sciences Sector 3Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 2Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 3Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 4Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 5Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 6Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 7Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 8Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 9Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 10Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 11Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 12Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 13Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 14Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 15
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
(Date:3/20/2015)... 20, 2015 Research and Markets ... the "India Sensors Market Forecast and Opportunities ... The sensor market is projected to grow at ... Consumer electronics, automotive, industrial and healthcare sectors are ... country. In addition, adoption of MEMS technology in ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... a fungal infection which is one of the major causes of ... PLoS Pathogens , funded by the Wellcome Trust and the ... evolved and spread out of Africa and into Asia. ... fungi. One particular strain of the fungus known as ...
... April 1, 2011 Aware, Inc. (NASDAQ: AWRE ... telecommunications and biometrics industries, today announced that Edmund C. Reiter ... Executive Officer and director of the board of the company ... and Kevin T. Russell, General Counsel have been named co-CEOs ...
... Fla., April 6, 2011 Ceelox, Inc. (OTCBB: CELO) ... PC Edition which operates on computers running the Windows ... has redesigned their authentication approach to leverage the recent ... Biometric Framework (WBF) provides support for fingerprint biometric devices ...
Cached Biology News:Scientists track evolution and spread of deadly fungus, one of the world's major killers 2Aware, Inc. Announces Resignation of Chief Executive Officer 2Aware, Inc. Announces Resignation of Chief Executive Officer 3Ceelox Offers Beta Release of Ceelox ID 7 for Personal Computers 2
... scale kinase profiling, quantitative measurement of ... research built on the flexible and ... These microarrays are available as part ... - Peptide Microarray Service. ...
... Microarrays designed for immunological studies, ... on the flexible and powerful Paraflo ... are available as part of our ... Custom Probe Content Probe ...
... Molecular Imaging (MI) Software for use in ... and drug discovery applications. The Regulatory Edition ... Drug Administrations Code of Federal Regulations Title ... [21 CFR Part 11]. KODAK MI Software, ...
... Arrays are intended for laboratory research use ... in neutral buffered formalin and embedded in ... performed by certified pathologists. Tissue cores ... relocated into a new recipient paraffin block, ...
Biology Products: